Europska Unija - islandski - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

n.v. organon* - losartanum kalíum - filmuhúðuð tafla - 50 mg

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

n.v. organon* - losartanum kalíum - filmuhúðuð tafla - 100 mg

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - losartanum kalíum - filmuhúðuð tafla - 50 mg

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - losartanum kalíum - filmuhúðuð tafla - 12,5 mg

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

eql pharma ab - prednisolonum inn - tafla - 5 mg

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - stungulyf, dreifa - 14,0/3,5 % w/v

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

vital pharma nordic aps - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 2 g

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn

Island - islandski - LYFJASTOFNUN (Icelandic Medicines Agency)

vifor france - ferricum carboxymaltosum inn - stungulyf/innrennslislyf, ördreifa - 50 mg/ml